DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

SHINE secures rights to new method for Lutetium-177 production Generate Lu-177 at greater speed and scale

FDA gives green light to new United Imaging PET/MR scanner The uPMR 790 HD TOF performs total-body scans within 20 minutes

FDA reminder for properly eluting rubidium 82 generators prompted by 'recent incidents' Using incorrect solutions puts patients at risk

Generating higher quality PET images 100x faster at MSK 'No one has done PET imaging in this way before'

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

PET scan of cardiac amyloidosis

PET can visualize hard-to-find, often fatal heart condition known as amyloidosis

par John W. Mitchell , Senior Correspondent
An Australian team of researchers has put an existing Alzheimer's radiotracer to work detecting amyloidosis, a heart problem that, once diagnosed through traditional biopsy, can mean a poor prognosis for patients.

"The study was conceived at a time when amyloid radiotracers...had been introduced for detecting amyloid plaques in the brain of Alzheimer's patients," W. Phillip Law, corresponding author and Radiologist, and Nuclear Medicine Specialist at Princess Alexandra Hospital in Brisbane, told HCB News. "We were curious whether it would be just as effective in the identification of amyloid deposition in heart muscle, as this could potentially be a very useful investigation for the many amyloid patients we see at our hospital."

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

The Princess Alexandra Hospital in Brisbane, Australia, is a major tertiary referral center and university-affiliated hospital with an amyloidosis clinic that provides integrated clinical care for the majority of patients with amyloidosis or suspected amyloidosis in the state. The study was just published in this month's issue of The Journal of Nuclear Medicine.

According to Law, the study was unique in that it included symptomatic patients rather than just normal subjects without heart problems. The condition – amyloidosis, which leads to dysfunction of the heart – is caused by calcium build-up in the heart. Median survival rates can be less than six months in untreated patients with certain types of amyloidosis. In yet other patients the condition can involve other organs, with the heart most at risk.

"Cardiac amyloidosis is notoriously difficult to diagnose because the first signs and symptoms of the disease are nonspecific and usually attributed to other conditions, resulting in delayed diagnosis and late introduction of appropriate treatment," said Law. "With considerable progress being made in the treatment of amyloidosis, which will hopefully improve survival from the disease, early diagnosis has never been more important."

He added that the radiotracer fluorine-18 (F-18)-florbetaben used in the PET study appeared to be very promising in identifying the heart condition. But he described the findings as "preliminary" based on a small number of patients (14). Law said the findings need to be validated in a larger group of test subjects with different types of amyloid and non-amyloid heart disease.

"If shown to be just as useful in larger cohorts and for differentiating amyloid from other cardiac disorders, florbetaben PET could become a convenient, noninvasive test for diagnosing amyloid involvement of the heart," Law said.

He also noted that if the evidence continues to support the viability of this PET screening protocol, it could minimize or eliminate the need for invasive biopsy procedures. This, in turn, would reduce potential complications and cost of the procedures, reducing health care costs. The procedure might also simplify the diagnostic algorithm for cardiac amyloidosis.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019, Inc.